Drug Profile
Research programme: metabolic disorder therapeutics - Ember Therapeutics
Alternative Names: Brown adipose tissue activators - Ember Therapeutics; Brown fat activators - Ember Therapeutics; IrisinLatest Information Update: 05 Dec 2021
Price :
$50
*
At a glance
- Originator Ember Therapeutics
- Class Proteins; Small molecules
- Mechanism of Action Aldehyde oxidoreductase inhibitors; Mitochondrial protein modulators; Thiolester hydrolase inhibitors; TRPV4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Metabolic disorders; Obesity; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-disorders in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Metabolic-disorders in USA (PO, Pill)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA (Parenteral)